ArticleBMC cancer2026

Evaluation of venetoclax and hypomethylating agent combination therapy in acute myeloid leukemia: a real-life, single-center experience.

Kübra Oral et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.